Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (824)	9/10/2001 9:31:17 AM
From: tuck	Read Replies (1) \| Respond to of 1784

>>SUNNYVALE, Calif., Sept. 10 /PRNewswire/ -- Molecular Devices Corporation (Nasdaq: MDCC - news), a leader in innovative solutions for drug discovery and life sciences research, today announced the launch of the CatchPoint(TM) Cyclic AMP Assay Kit. This kit represents the first of a series of assays that are expected to provide the highest available sensitivity, pre-packaged in a 384-well plate format compatible with high-throughput screening. Cyclic AMP is an important signaling molecule for drug discovery, but current screening tools are relatively insensitive, expensive, and often use radioisotopes for detection purposes. The CatchPoint(TM) assay is non-radioactive and ten times more sensitive than alternative commercial assays. The assay is pre-packaged for high-throughput screening in 384-well plates, and the novel formulation generates a very robust fluorescent readout that resists interference from drug compounds. The assay protocol does not require exact temperatures or incubation times, making it well-suited for batch processing or robotic handling. ``In applications where cAMP levels are low, such as drug discovery screens for agonists of Gi-coupled GPCRs, sensitivity is important,'' stated Stephen Oldfield, Ph.D. and Marketing Director for Drug Discovery at Molecular Devices. ``This kit provides the highest level of sensitivity available in an HTS format. With its precise fluorescent readout, the kit leverages Molecular Devices' significant installed base of Analyst(TM), Acquest(TM) and SPECTRAmax® GEMINI microplate readers, providing a solution for all stages in the drug discovery pipeline.''<< snip Cheers, Tuck